210 related articles for article (PubMed ID: 34888676)
1. Unmasking Fracture Risk in Type 2 Diabetes: The Association of Longitudinal Glycemic Hemoglobin Level and Medications.
Wang B; Wang Z; Poundarik AA; Zaki MJ; Bockman RS; Glicksberg BS; Nadkarni GN; Vashishth D
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1390-e1401. PubMed ID: 34888676
[TBL] [Abstract][Full Text] [Related]
2. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
[TBL] [Abstract][Full Text] [Related]
3. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
Fu AZ; Sheehan JJ
Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
[TBL] [Abstract][Full Text] [Related]
4. Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study.
Ke C; Stukel TA; Shah BR; Lau E; Ma RC; So WY; Kong AP; Chow E; Chan JCN; Luk A
PLoS Med; 2020 Sep; 17(9):e1003316. PubMed ID: 32946450
[TBL] [Abstract][Full Text] [Related]
5. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database.
Mamza J; Mehta R; Donnelly R; Idris I
Diabetes Technol Ther; 2016 Feb; 18(2):85-92. PubMed ID: 26752504
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
[TBL] [Abstract][Full Text] [Related]
7. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Thayer S; Chow W; Korrer S; Aguilar R
Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and management of COVID-19-related severity in people with type 2 diabetes.
Wang B; Glicksberg BS; Nadkarni GN; Vashishth D
BMJ Open Diabetes Res Care; 2021 Sep; 9(1):. PubMed ID: 34493495
[TBL] [Abstract][Full Text] [Related]
9. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.
Koye DN; Montvida O; Paul SK
Drugs; 2020 Apr; 80(5):477-487. PubMed ID: 32141024
[TBL] [Abstract][Full Text] [Related]
10. Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes.
Pantalone KM; Misra-Hebert AD; Hobbs TM; Wells BJ; Kong SX; Chagin K; Dey T; Milinovich A; Weng W; Bauman JM; Burguera B; Zimmerman RS; Kattan MW
J Diabetes; 2018 Mar; 10(3):192-199. PubMed ID: 28976724
[TBL] [Abstract][Full Text] [Related]
11. Risk of fractures and diabetes medications: a nationwide cohort study.
Choi HJ; Park C; Lee YK; Ha YC; Jang S; Shin CS
Osteoporos Int; 2016 Sep; 27(9):2709-2715. PubMed ID: 27080708
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
13. Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus.
Lee RH; Sloane R; Pieper C; Lyles KW; Adler RA; Van Houtven C; LaFleur J; Colón-Emeric C
J Bone Miner Res; 2019 Nov; 34(11):2045-2051. PubMed ID: 31269274
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Cummings DM; Tanenberg RJ
Diabetes Res Clin Pract; 2015 Aug; 109(2):378-88. PubMed ID: 26059071
[TBL] [Abstract][Full Text] [Related]
15. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
McCoy RG; Lipska KJ; Van Houten HK; Shah ND
JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
[TBL] [Abstract][Full Text] [Related]
16. Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank.
Jiang G; Luk AO; Tam CHT; Lau ES; Ozaki R; Chow EYK; Kong APS; Lim CKP; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JYY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung SKS; Cheng YL; Chow CC; Pearson ER; So WY; Chan JCN; Ma RCW; ;
PLoS Med; 2020 Jul; 17(7):e1003209. PubMed ID: 32722720
[TBL] [Abstract][Full Text] [Related]
17. Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes.
Bae J; Kim YE; Lee M; Lee YH; Lee BW; Cha BS; Kang ES
Yonsei Med J; 2022 Jun; 63(6):539-544. PubMed ID: 35619577
[TBL] [Abstract][Full Text] [Related]
18. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Dombrowski S; Kostev K; Jacob L
Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and a Sulfonylurea in a Real-World Setting.
Aboubechara N; Ledesma VM; Niu F; Lee SM; Patel YA; Millares M; Hui RL
Perm J; 2020 Nov; 24():1-8. PubMed ID: 33482956
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.
Lim S; Ku EJ; Lee SY; Lee JH; Lee JE; Kim KM; Davies MJ
BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
